PROTEOMICS
蛋白质组学
基本信息
- 批准号:8436447
- 负责人:
- 金额:$ 6.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-03-01 至 2018-02-28
- 项目状态:已结题
- 来源:
- 关键词:AcylationBiologicalBiological MarkersCancer CenterCancer Center Support GrantCancer EtiologyCell physiologyCellsClientClinicalCollaborationsCommitConsultationsDataDatabasesDetectionDevelopmentDiseaseDissociationElectron TransportEnsureEquipmentFee-for-Service PlansFeedbackFeesFundingGelGoalsIndividualInstitutesInstructionKaplan Cancer CenterLabelLaboratoriesLiquid ChromatographyMALDI-TOF Mass SpectrometryMalignant NeoplasmsMass Spectrum AnalysisMedicalMethodsPeptidesPhosphorylationPhosphorylation SitePost-Translational Protein ProcessingPrimary Cell CulturesProcessProtein AnalysisProteinsProteolysisProteomicsProteomics Shared ResourceRecruitment ActivityRelative (related person)RelianceResearchResearch PersonnelResource SharingResourcesScientistScreening for cancerSequence DeterminationServicesSignal TransductionSiteStructureTechnical ExpertiseTechniquesTechnologyTechnology AssessmentTissuesUbiquitinationUnited States National Institutes of Healthbasecancer therapycost effectivedesignglycosylationinnovative technologiesinstrumentinterestnew technologypreventprogramsprotein aminoacid sequenceprotein functionprotein structureresearch studysuccesstandem mass spectrometry
项目摘要
PROJECT SUMMARY (See instructions): The Proteomics Shared Resource provides state-of the-art biological mass spectrometry analyses to cancer researchers at NYU to help them identify and characterize proteins of medical importance. In many cases, it is only by studying proteins directly that one can achieve a useful understanding of the processes that underly the functioning of cells and tissues in normal and diseased states such as cancer. The shared resource has the capability to identify single, hundreds or even thousands of proteins in a single analysis, often at subfemtomole levels, by state of the art liquid chromatography-tandem mass spectrometry followed by database searching or de novo sequence determination. In most cases the facility strives to obtain accurate information about the absolute and/or relative quantities of these proteins from cells under various conditions to obtain important information about the functioning of the proteins. The shared resource also has special expertise in characterizing posttranslational modifications of proteins such as phosphorylation, acylation, glycosylation and ubiquitination. In addition to its technical expertise, one of the strengths of the facility is its ability to advise clients in the design and interpretation of experiments so that useful data can be obtained and meaningful information can be had from these data. Reliance on cutting edge technology and its expert and dedicated staff allow these services to be performed in a cost effective manner. Indeed, many experiments by investigators at NYU and the NYU Cancer Institute (NYUCI) could not have been done without the assistance of the Shared Resource. The Resource also has established a Clinical Proteomics Core for the detection of protein and peptide biomarkers for the early detection of cancer.
项目摘要(参见说明):蛋白质组学共享资源为纽约大学的癌症研究人员提供最先进的生物质谱分析,帮助他们识别和表征具有医学重要性的蛋白质。在许多情况下,只有通过直接研究蛋白质,人们才能对细胞和组织在正常和疾病状态(例如癌症)下的功能过程有一个有用的了解。共享资源能够通过最先进的液相色谱-串联质谱法,然后进行数据库搜索或从头序列测定,在单次分析中识别单个、数百甚至数千种蛋白质,通常在亚飞摩尔水平。在大多数情况下,该设施致力于在各种条件下从细胞中获取有关这些蛋白质的绝对和/或相对数量的准确信息,以获得有关蛋白质功能的重要信息。共享资源还具有表征蛋白质翻译后修饰(例如磷酸化、酰化、糖基化和泛素化)的特殊专业知识。除了技术专长之外,该设施的优势之一是能够为客户提供实验设计和解释方面的建议,以便获得有用的数据并从这些数据中获得有意义的信息。依靠尖端技术及其专家和敬业的员工,使这些服务能够以具有成本效益的方式提供。事实上,如果没有共享资源的帮助,纽约大学和纽约大学癌症研究所 (NYUCI) 的研究人员不可能完成许多实验。该资源还建立了临床蛋白质组学核心,用于检测蛋白质和肽生物标志物,从而早期检测癌症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
William L. Carroll其他文献
Quantitative studies of APUD cells in airways and gut in the guinea pig
豚鼠气道和肠道中 APUD 细胞的定量研究
- DOI:
10.1007/bf02713870 - 发表时间:
1983-12-01 - 期刊:
- 影响因子:5
- 作者:
A. Marchevsky;William L. Carroll;Joseph Jacobs;S. Keller;J. Kleinerman - 通讯作者:
J. Kleinerman
Acute lymphoblastic leukemia
急性淋巴细胞白血病
- DOI:
10.1016/s0031-3955(05)70532-0 - 发表时间:
2022 - 期刊:
- 影响因子:0
- 作者:
Pallavi M Pillai;William L. Carroll - 通讯作者:
William L. Carroll
Alternative V kappa gene rearrangements in a murine B cell lymphoma. An explantation for idiotypic heterogeneity
小鼠 B 细胞淋巴瘤中的替代 V kappa 基因重排。
- DOI:
- 发表时间:
1988 - 期刊:
- 影响因子:15.3
- 作者:
William L. Carroll;Charlie O. Starnes;Ronald Levy;S. Levy - 通讯作者:
S. Levy
Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits.
针对鼠 B 细胞淋巴瘤的独特型疫苗接种。
- DOI:
10.4049/jimmunol.139.8.2825 - 发表时间:
1987-10-15 - 期刊:
- 影响因子:4.4
- 作者:
Michael J. Campbell;William L. Carroll;Shinichiro Kon;Kristiaan Thielemans;Jonathan B. Rothbard;S. Levy - 通讯作者:
S. Levy
Acute lymphoblastic leukemia
急性淋巴细胞白血病
- DOI:
- 发表时间:
2022 - 期刊:
- 影响因子:0
- 作者:
Pallavi M Pillai;William L. Carroll - 通讯作者:
William L. Carroll
William L. Carroll的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('William L. Carroll', 18)}}的其他基金
Remodeling of 3D chromatin in B cell acute leukemia and its impact on clinical outcome
B细胞急性白血病3D染色质重塑及其对临床结果的影响
- 批准号:
10184002 - 财政年份:2021
- 资助金额:
$ 6.02万 - 项目类别:
Remodeling of 3D chromatin in B cell acute leukemia and its impact on clinical outcome
B细胞急性白血病3D染色质重塑及其对临床结果的影响
- 批准号:
10631888 - 财政年份:2021
- 资助金额:
$ 6.02万 - 项目类别:
Remodeling of 3D chromatin in B cell acute leukemia and its impact on clinical outcome
B细胞急性白血病3D染色质重塑及其对临床结果的影响
- 批准号:
10381569 - 财政年份:2021
- 资助金额:
$ 6.02万 - 项目类别:
相似国自然基金
基于肿瘤病理图片的靶向药物敏感生物标志物识别及统计算法的研究
- 批准号:82304250
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于纵向队列的老年人躯体恢复力的风险因素和生物标志物研究
- 批准号:82301768
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
通过DNA甲基化研究高原低氧暴露下衰老的生物标志物
- 批准号:32300533
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
改性卤氧化铋基纳米阵列微流控-光电化学生物传感器构建与肝癌标志物检测应用研究
- 批准号:22304068
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于肝癌多组学数据集成的肝癌生物标志物智能解析与预测方法研究
- 批准号:62333018
- 批准年份:2023
- 资助金额:237 万元
- 项目类别:重点项目
相似海外基金
Time-restricted eating: Is it an efficacious tool for weight loss maintenance
限时饮食:是减肥维持的有效工具吗
- 批准号:
10591316 - 财政年份:2023
- 资助金额:
$ 6.02万 - 项目类别:
Discovery of phosgene and chlorine gas modes of action and therapeutic targets using chemoproteomic profiling strategies
使用化学蛋白质组学分析策略发现光气和氯气的作用模式和治疗靶点
- 批准号:
10883970 - 财政年份:2023
- 资助金额:
$ 6.02万 - 项目类别:
Protease Stable N-Terminally Modified Therapeutic Peptides
蛋白酶稳定的 N 末端修饰的治疗性肽
- 批准号:
10484456 - 财政年份:2022
- 资助金额:
$ 6.02万 - 项目类别: